Thairm Bio leads $21m funding of EnteroBiotix

The Glasgow, Scotland biopharmaceutical company raises an oversubscribed $21.5m round.

Scottish company EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, announced the final closing of its oversubscribed UK £15.5 million ($21.5 million) round. The Series A financing was led by Thairm Bio and includes new US-based investor Kineticos Ventures, joining existing investors including Scottish Enterprise and SIS Ventures.

Source: Press release